Company intelligence
Marken
UPS Healthcare Precision Logistics | Marken, MNX, & Polar Speed Combined
About Marken
Marken, UPS Healthcare Precision Logistics (formerly Marken, MNX & Polar Speed), the clinical and advanced therapy subsidiary of UPS Healthcare, unites expertise across healthcare and complex secure logistics to drive the success of our clients through innovation. Operating in 220+ countries and territories, our team of 4,000 experts orchestrate over 6.6M shipments annually at all temperature ranges across our harmonized air, sea and ground network. With a ready-now packaging catalog and global depot matrix, Marken overcomes the most complex and evolving industry challenges, mitigating risks to always make it happen. Marken offers a complete range of services that integrates drug supply, storage and distribution, advanced therapy, radio pharma logistics, patient-driven services, laboratory logistics, kitting solutions, and connected medical device management. By prioritizing quality and putting patients first, Marken ensures time and temperature-critical shipments reach those who need them most. We are ready. Now. Experience. Our Precision.
Verified activity
Signals from Marken
16 published signals
Presence & Recognition
Marken is exhibiting at stand 55 at Advanced Therapies Europe from 7th to 9th September to discuss clinical supply chain topics.
Reported by Andy Holloway
Operations & Supply
Marken expanded its network and global reach by insourcing D/I production.
Reported by Oliver Raab
Operations & Supply
Marken announced that dry ice production is now live at its Nairobi depot in Kenya, enabling approximately 100 kg per hour of in-house production.
Reported by Marken
Presence & Recognition
Marken is hosting five events in Barcelona, Montevideo, Boston, Osaka, and Quintana Roo from September 7 to 9, 10, 15-16, 30-31, and 23-26, respectively, focusing on scaling advanced therapies, evolving supply chains, connected clinical trials, innovation, and wider access.
Reported by Marken
Customers & Market
Marken noted that Octapharma in Vienna expanded production volumes by 50%.
Reported by Oliver Raab
Customers & Market
Marken noted that Boehringer Ingelheim in Vienna provides major cancer research and biopharmaceutical production.
Reported by Oliver Raab
Customers & Market
Marken mentioned that Takeda, Vienna, and Linz supply plasma-derived therapies, biologics, and pre-filled syringes globally.
Reported by Oliver Raab
Customers & Market
Marken noted that Novartis and Kundl/Schaftenau are advanced biologics including monoclonal antibodies and therapeutic proteins.
Reported by Oliver Raab
Customers & Market
Marken highlighted that Sandoz and Kundl are strategic antibiotic hubs with annual capacity for approximately 240 million packs.
Reported by Oliver Raab
Customers & Market
Marken noted that Austria generated around €4.8bn in pharmaceutical production in 2024, while pharma exports approached €20bn.
Reported by Oliver Raab
Customers & Market
Marken reported that Austria's pharmaceutical market reached approximately €7.5bn in 2025, up from €6.9bn in 2024.
Reported by Oliver Raab
Customers & Market
Marken highlighted that for pharma logistics, the equation is compelling with clinical trials, CDMOs, biologics, plasma products, specialty medicines, and global exports forming high-value, highly regulated, and temperature-sensitive logistics flows.
Reported by Oliver Raab
Customers & Market
Marken noted that some forecasts predict individual Austrian pharma segments such as APIs growing around 4 to 6 percent CAGR through 2035.
Reported by Oliver Raab
Customers & Market
Marken mentioned that Austria introduced an accelerated authorization pathway for initially mononational clinical trials to compete for research.
Reported by Oliver Raab
Customers & Market
Marken noted that between 2020 and 2024, an average of 463 industry-sponsored clinical trials were active annually treating around 2,300 patients per year.
Reported by Oliver Raab
Customers & Market
Marken highlighted that Austria offers highly specialized CDMO capabilities including APIs, sterile fill and finish, plasmid DNA, mRNA, recombinant proteins, and complex biologics.
Reported by Oliver Raab